| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
20,430,000 |
| Market
Cap: |
1.37(B) |
| Last
Volume: |
2,387,520 |
Avg
Vol: |
2,380,888 |
| 52
Week Range: |
$38.04 - $69.69 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ANI Pharmaceuticals is a bio-pharmaceutical company focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Co.'s products include: Candesartan Hydrochlorothiazide, Fenofibrate, Fluvoxamine, Hydrocortisone Enema, Lithium Carbonate ER, Mesalamine, Propranolol ER, Terbutaline, and Vancomycin.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
250,132 |
394,694 |
1,191,358 |
1,409,424 |
| Total Sell Value |
$16,523,610 |
$24,268,720 |
$69,977,407 |
$78,350,476 |
| Total People Sold |
8 |
9 |
11 |
11 |
| Total Sell Transactions |
21 |
39 |
80 |
83 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Arnold Charlotte C. |
Chief Financial Officer |
• – – |
2013-11-22 |
4 |
D |
$13.43 |
$18,320 |
D/D |
(1,364) |
30,043 |
|
- |
|
| Arnold Charlotte C. |
Chief Financial Officer |
• – – |
2013-11-22 |
4 |
A |
$0.00 |
$0 |
D/D |
3,675 |
31,407 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2013-11-22 |
4 |
D |
$13.42 |
$75,717 |
D/D |
(5,644) |
84,435 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2013-11-22 |
4 |
A |
$0.00 |
$0 |
D/D |
12,139 |
90,079 |
|
- |
|
| Arnold Charlotte C. |
Chief Financial Officer |
• – – |
2013-11-13 |
4 |
D |
$11.32 |
$15,441 |
D/D |
(1,364) |
27,732 |
|
- |
|
| Arnold Charlotte C. |
Chief Financial Officer |
• – – |
2013-11-13 |
4 |
A |
$0.00 |
$0 |
D/D |
3,675 |
29,096 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2013-11-13 |
4 |
D |
$11.32 |
$63,887 |
D/D |
(5,644) |
77,940 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2013-11-13 |
4 |
A |
$0.00 |
$0 |
D/D |
12,139 |
83,584 |
|
- |
|
| Mangano Ross J |
Director |
– • – |
2013-11-07 |
4 |
B |
$11.27 |
$101,430 |
D/D |
9,000 |
21,914 |
2.39 |
- |
|
| Arnold Charlotte C. |
Chief Financial Officer |
• – – |
2013-11-06 |
4 |
D |
$11.09 |
$15,130 |
D/D |
(1,364) |
25,421 |
|
- |
|
| Arnold Charlotte C. |
Chief Financial Officer |
• – – |
2013-11-06 |
4 |
A |
$0.00 |
$0 |
D/D |
3,675 |
26,785 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2013-11-06 |
4 |
D |
$11.10 |
$62,673 |
D/D |
(5,644) |
71,445 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2013-11-06 |
4 |
A |
$0.00 |
$0 |
D/D |
12,139 |
77,089 |
|
- |
|
| Mangano Ross J |
Director |
– • – |
2013-11-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,310 |
12,914 |
|
- |
|
| Marshbanks Tracy |
Director |
– • – |
2013-11-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,310 |
8,310 |
|
- |
|
| Penn Thomas A. |
Director |
– • • |
2013-11-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,310 |
8,310 |
|
- |
|
| Holubow Fred |
Director |
– • – |
2013-11-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,310 |
14,733 |
|
- |
|
| Raynor Daniel |
Director |
– • – |
2013-11-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,310 |
8,310 |
|
- |
|
| Brown Robert E. Jr |
Director |
– • • |
2013-11-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,310 |
8,310 |
|
- |
|
| Arnold Charlotte C. |
Chief Financial Officer |
• – – |
2013-10-30 |
4 |
D |
$10.07 |
$13,735 |
D/D |
(1,364) |
23,110 |
|
- |
|
| Arnold Charlotte C. |
Chief Financial Officer |
• – – |
2013-10-30 |
4 |
A |
$0.00 |
$0 |
D/D |
3,675 |
24,474 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2013-10-30 |
4 |
D |
$10.08 |
$56,873 |
D/D |
(5,644) |
64,950 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2013-10-30 |
4 |
A |
$0.00 |
$0 |
D/D |
12,139 |
70,594 |
|
- |
|
| Arnold Charlotte C. |
Chief Financial Officer |
• – – |
2013-10-23 |
4 |
D |
$10.09 |
$13,768 |
D/D |
(1,364) |
20,799 |
|
- |
|
| Arnold Charlotte C. |
Chief Financial Officer |
• – – |
2013-10-23 |
4 |
A |
$0.00 |
$0 |
D/D |
3,675 |
22,163 |
|
- |
|
707 Records found
|
|
Page 20 of 29 |
|
|
0.14 (0.21%) 
